A major step toward simpler drug development has been taken at the University of Gothenburg. In a new study, researchers have developed stable boron-fluorine compounds that make it possible to ...

More than 100 million people in the United States suffer from metabolic dysfunction-associated steatotic liver disease (MASLD), characterized by a buildup of fat in the liver. This condition can lead ...

A new analysis of drug trials used to approve medicines in the United States shows how far modern medicine still has to go to ...

An international research consortium, led by scientists at VIB and UGent, has developed a new platform that could change how ...

Established drugs were repurposed, “me-too” drugs were approved, and even the few new biological approaches lacked clinical ...

Backed with $82 million and led by two of BioMarin’s former executives, Mendra plans to acquire rare disease assets and use ...

Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

Balasegaram is executive director of the Global Antibiotic Research & Development Partnership. No matter how carefully we use the antibiotics we have, drug resistant infections will continue to gain ...

Forbes contributors publish independent expert analyses and insights. Gil Press writes about technology, entrepreneurs and innovation. Will AI transform the typical trials and tribulations of drug ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...

“There are over 600,000 drugs in the Korea Chemical Bank alone. It felt overwhelming to find a drug that perfectly fits the protein structure we’re targeting among them. That’s when I thought of AI ...